Moneycontrol

Moneycontrol PRO

you are here: HomeNewsBusinessEarningsWhy SBICap remains bullish on Ranbaxy despite weak Q1 nos

SHOW NAMES

Trending Topics

business

Why SBICap remains bullish on Ranbaxy despite weak Q1 nos

SBI Cap Securities‘ Vivek Kumar continues to be bullish on Ranbaxy Laboratories despite its poor first quarter earnings; as against other brokerage houses like Quant Capital and Angel Broking which are advising to stay away from the stock.

first published: May 8, 2013 05:43 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347